Sulfamides as novel histone deacetylase inhibitors.
暂无分享,去创建一个
Alain Ajamian | Sylvain Lefebvre | Alina Nicolescu | David Smil | Eric Therrien | S. Leit | M. Fournel | Ai-hua Lu | Zuomei Li | J. Rahil | J. Besterman | D. Smil | M. Allan | Y. Chantigny | S. Manku | Natalie N. M. Nguyen | Eric Therrien | R. Déziel | Samuel Montcalm | Zuomei Li | Robert Déziel | Jubrail Rahil | Jeffrey M Besterman | Silvana Leit | Marielle Fournel | Natalie Nguyen | Ai-Hua Lu | A. Nicolescu | Martin Allan | Sukhdev Manku | Andrea J Petschner | Amal Wahhab | Yves Chantigny | Samuel Montcalm | Theresa P Yan | A. Wahhab | T. Yan | A. Ajamian | S. Lefèbvre
[1] A. V. van Kuilenburg,et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.
[2] Christine G. Espino,et al. Synthesis of 1,3-Difunctionalized Amine Derivatives through Selective C−H Bond Oxidation , 2001 .
[3] R. De Francesco,et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] Michael Rowley,et al. A series of novel, potent, and selective histone deacetylase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.
[5] A. C. Krueger,et al. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. , 2006, Bioorganic & medicinal chemistry letters.
[6] Takayoshi Suzuki,et al. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. , 2005, Bioorganic & medicinal chemistry letters.
[7] R. De Francesco,et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. , 2008, Journal of medicinal chemistry.
[8] S. Horinouchi,et al. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase , 1999, Oncogene.
[9] A. Kalita,et al. (2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors , 2004 .
[10] Sylvain Lefebvre,et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.
[11] P. Finn,et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. , 2003, Molecular cancer therapeutics.
[12] M. K. Pflum,et al. Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.
[13] Yukihiro Itoh,et al. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. , 2007, Journal of medicinal chemistry.
[14] Andreas Schwienhorst,et al. Histone deacetylases—an important class of cellular regulators with a variety of functions , 2007, Applied Microbiology and Biotechnology.
[15] S. Campbell,et al. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. , 1990, Journal of medicinal chemistry.
[16] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[17] Stuart L Schreiber,et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. McComsey,et al. Carbonic anhydrase-II inhibition. what are the true enzyme-inhibitory properties of the sulfamide cognate of topiramate? , 2008, Journal of medicinal chemistry.
[19] D. Faller,et al. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? , 2003, Current cancer drug targets.
[20] M. Binaschi,et al. Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.
[21] Therapeutic potential of sulfamides as enzyme inhibitors , 2006, Medicinal research reviews.
[22] C. Supuran,et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. , 2006, Journal of medicinal chemistry.
[23] C. Maroun,et al. Histone deacetylase inhibitors: latest developments, trends and prospects. , 2005, Current medicinal chemistry. Anti-cancer agents.
[24] M. Janicot,et al. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry,Biology and Clinical Benefit , 2007 .
[25] P. Atadja,et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. , 2006, Cancer research.
[26] A. Ho,et al. Chromosomal organization and localization of the novel class IV human histone deacetylase 11 gene. , 2005, International journal of molecular medicine.
[27] J. R. Somoza,et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. , 2004, Structure.
[28] P. Devillier,et al. New calcium antagonists: synthesis, X-ray analysis, and smooth muscle relaxing effect of 3-[O-(benzyl-substituted)-oximino-ethers]-hexahydroazepin-2,3- diones. , 1999, Bioorganic & medicinal chemistry.
[29] Andrea Scozzafava,et al. Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II with sulfamide derivatives. , 2003, Bioorganic & medicinal chemistry letters.
[30] Ø. Bruserud,et al. Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells , 2007 .
[31] Keith B Glaser,et al. Trifluoromethyl ketones as inhibitors of histone deacetylase. , 2002, Bioorganic & medicinal chemistry letters.
[32] A. Kohara,et al. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[33] M. Jung,et al. Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors , 1997 .
[34] D M Schmatz,et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] Isabelle Paquin,et al. Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. , 2008, Journal of medicinal chemistry.